Cipla: Citigroup on Cipla Buy with Target Price ₹1,530 as rising competition in generic Symbicort (Teva + Viatris) increases urgency for Cipla’s timely US FDA approval to capture market share and sustain growth.

 28 Apr 2026 08:56 AM

Cipla: Citigroup on Cipla Buy with Target Price ₹1,530 as rising competition in generic Symbicort (Teva + Viatris) increases urgency for Cipla’s timely US FDA approval to capture market share and sustain growth.

Cipla: Macquarie Notes Says USFDA Import Alert On Pharmathen’s Greece Plant Blocks Lanreotide Supplies To The US. || ~US$90–100mn Revenue At Risk; Earlier Restart Hopes For Fy27 Now Unlikely.

 24 Apr 2026 12:34 PM

Cipla: Macquarie Notes Says USFDA Import Alert On Pharmathen’s Greece Plant Blocks Lanreotide Supplies To The US. || ~US$90–100mn Revenue At Risk; Earlier Restart Hopes For Fy27 Now Unlikely.

Cipla: Co's Partner Unit - Pharmathen's Rodopi - As Per FDA's Website Is Under Import Alert || Cipla Has Partnership With Pharmathen International S.A. - Specifically Its Rodopi, Greece Facility

 24 Apr 2026 09:21 AM

Cipla: Co's Partner Unit - Pharmathen's Rodopi - As Per FDA's Website Is Under Import Alert || Cipla Has Partnership With Pharmathen International S.A. - Specifically Its Rodopi, Greece Facility

Cipla: This Unit Manufactures Lanreotide Injection || Analyst Expected $50-60 Million Revenue In Fy27 And $100 Million In Fy28 From Lanreotide Injection

 24 Apr 2026 09:22 AM

Cipla: This Unit Manufactures Lanreotide Injection || Analyst Expected $50-60 Million Revenue In Fy27 And $100 Million In Fy28 From Lanreotide Injection

Cipla: Co. Receives U.S. FDA Approval For First AB-Rated Generic Of Ventolin® HFA; Product Expected To Launch In H1 Fy 2026-27; Enhances U.S. Respiratory Portfolio. || US Sales Of USD 1.5b

 23 Apr 2026 09:52 AM

Cipla: Co. Receives U.S. FDA Approval For First AB-Rated Generic Of Ventolin® HFA; Product Expected To Launch In H1 Fy 2026-27; Enhances U.S. Respiratory Portfolio. || US Sales Of USD 1.5b

Cipla: U.S. FDA Inspects Goa Plant From April 6–17, 2026, Issues Two Form 483 Observations

 17 Apr 2026 04:36 PM

Cipla: U.S. FDA Inspects Goa Plant From April 6–17, 2026, Issues Two Form 483 Observations

Cipla: UBS on Cipla Neutral, Target Price Rs 1400 (cut from 1750) as strong pipeline supports medium-term growth, but near-term supply headwinds including Lanreotide issues limit catalysts and weigh on outlook.

 25 Mar 2026 08:56 AM

Cipla: UBS on Cipla Neutral, Target Price Rs 1400 (cut from 1750) as strong pipeline supports medium-term growth, but near-term supply headwinds including Lanreotide issues limit catalysts and weigh on outlook.

Cipla: Approves Investment Up To $100 Million In Equity Shares Of Cipla (EU) Limited And Agrees To Merge Inzpera Health Sciences Limited With The Company.

 19 Mar 2026 05:34 PM

Cipla: Approves Investment Up To $100 Million In Equity Shares Of Cipla (EU) Limited And Agrees To Merge Inzpera Health Sciences Limited With The Company.

Cipla: Morgan Stanley maintains Underweight on Cipla with Target Price Rs 1,211, citing Lanreotide injection batch recalls from Pharmathen’s Radopi facility, likely delaying US resupply, risking market share loss, and potential downside to FY27–FY28 earnings.

 11 Mar 2026 09:06 AM

Cipla: Morgan Stanley maintains Underweight on Cipla with Target Price Rs 1,211, citing Lanreotide injection batch recalls from Pharmathen’s Radopi facility, likely delaying US resupply, risking market share loss, and potential downside to FY27–FY28 earnings.

Cipla: Cipla USA Starts Recall of Lanreotide Injection Batches, Leading to Short-Term Supply Issues.

 10 Mar 2026 08:05 AM

Cipla: Cipla USA Starts Recall of Lanreotide Injection Batches, Leading to Short-Term Supply Issues.

Cipla: Forms 60:40 Joint Venture With Kemwell Biopharma To Create And Market Biologic Products, Both Partners To Invest Up To 100 Million Rupees

 02 Mar 2026 08:11 PM

Cipla: Forms 60:40 Joint Venture With Kemwell Biopharma To Create And Market Biologic Products, Both Partners To Invest Up To 100 Million Rupees

Cipla: New Subsidiary Established in Saudi Arabia

 02 Mar 2026 07:39 PM

Cipla: New Subsidiary Established in Saudi Arabia

Cipla: MS on Cipla UW, Target Price Rs 1211

 23 Feb 2026 09:14 AM

Cipla: MS on Cipla UW, Target Price Rs 1211

Cipla: USFDA inspection At Co’s Subsidiary Pharmathen’s Facility Was Classified As Official Action Indicated.

 21 Feb 2026 06:16 PM

Cipla: USFDA inspection At Co’s Subsidiary Pharmathen’s Facility Was Classified As Official Action Indicated.

Eli Lilly Aims To Make India A Key Global Export Hub, Says Executive As Part Of Their Supply Chain Strategy - RTRS ( CIPLA )

 18 Feb 2026 09:04 AM

Eli Lilly Aims To Make India A Key Global Export Hub, Says Executive As Part Of Their Supply Chain Strategy - RTRS ( CIPLA )

CIPLA: USFDA Inspects CIPLA's InvaGen Facility In Hauppauge, USA, Receiving Two Observations In Form 483.

 10 Feb 2026 08:57 AM

CIPLA: USFDA Inspects CIPLA's InvaGen Facility In Hauppauge, USA, Receiving Two Observations In Form 483.

CIPLA: Co Reports No Negative Findings From GST Department Inspection in Maharashtra.

 09 Feb 2026 06:45 AM

CIPLA: Co Reports No Negative Findings From GST Department Inspection in Maharashtra.

Cipla: Company Reports Tax Department Begins Inspection At Its Facilities, No Financial Impact Expected

 05 Feb 2026 06:50 PM

Cipla: Company Reports Tax Department Begins Inspection At Its Facilities, No Financial Impact Expected

Cipla: Jefferies on Cipla Downgrade to U-P, TP cut to Rs 1170

 27 Jan 2026 09:10 AM

Cipla: Jefferies on Cipla Downgrade to U-P, TP cut to Rs 1170

Cipla: HSBC on Cipla Downgrade to Hold, TP cut to Rs 1285

 27 Jan 2026 09:11 AM

Cipla: HSBC on Cipla Downgrade to Hold, TP cut to Rs 1285